1-Ethyl-3-(3'-dimethylaminopropyl)carbodiimide → N-((1R)-6-(2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)-1,2,3,4-tetrahydronaphthalen-1-yl)-2-(3-oxo-1-tosylpiperazin-2-yl)acetamide
反応式
[CH3:1][C:2]1[N:6]=[C:5]([C:7]2[CH:12]=[CH:11][CH:10]=[CH:9][C:8]=2[C:13]2[CH:14]=[C:15]3[C:20](=[CH:21][CH:22]=2)[C@H:19]([NH2:23])[CH2:18][CH2:17][CH2:16]3)[O:4][N:3]=1.[O:24]=[C:25]1[NH:30][CH2:29][CH2:28][N:27]([S:31]([C:34]2[CH:40]=[CH:39][C:37]([CH3:38])=[CH:36][CH:35]=2)(=[O:33])=[O:32])[CH:26]1[CH2:41][C:42](O)=[O:43].CN(C(ON1N=NC2C=CC=NC1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F.CCN=C=NCCCN(C)C.CCN(C(C)C)C(C)C>C(Cl)Cl>[CH3:1][C:2]1[N:6]=[C:5]([C:7]2[CH:12]=[CH:11][CH:10]=[CH:9][C:8]=2[C:13]2[CH:14]=[C:15]3[C:20](=[CH:21][CH:22]=2)[C@H:19]([NH:23][C:42](=[O:43])[CH2:41][CH:26]2[C:25](=[O:24])[NH:30][CH2:29][CH2:28][N:27]2[S:31]([C:34]2[CH:40]=[CH:39][C:37]([CH3:38])=[CH:36][CH:35]=2)(=[O:33])=[O:32])[CH2:18][CH2:17][CH2:16]3)[O:4][N:3]=1参加物
7
反応物 5
生成物 1
試薬・触媒・溶媒 1
実験手順
To a 100 mL round bottom flask was added (1R)-6-(2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl)-1,2,3,4-tetrahydronaphthalen-1-amine (25.0 mg, 0.06 mmol), followed by 2-(3-oxo-1-tosylpiperazin-2-yl)acetic acid (50 mg, 0.016 mmol), dry CH2Cl2 (10 mL), HATU (12 mg, 0.03 mmol), EDCI (13 mg, 0.068 mmol) and hunig base (0.022 mL, 0.123 mmol). The resulting mixture was stirred at rt for 20 h. Removed solvent to dryness. Solvent was removed. The residue was purified by chromatography on silica gel. Elution with CH2Cl2:MeOH mixture (97:3) gave final compound. MS m/z: 600.3 (M+H). Calc'd. for C32H33N5O5S -599.71.s
後処理
- customSolvent was removed
- customThe residue was purified by chromatography on silica gel
- washElution with CH2Cl2
出典と根拠
- ORDレコード
- ord-e794a0f63a3e44afa4605e71b2873f10
- 出典データセット
- uspto-grants-2008_07
- 特許番号
- US07393852B2
反応ノート
読み込み中…